Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase

Rhea-AI Summary

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) presented an overview of its glaucoma franchise at the Ophthalmology Innovation Summit. The presentation highlighted growth in the U.S. and advancements towards market entry in Europe and Japan. Aerie focuses on developing therapies for open-angle glaucoma and ocular surface diseases. Its products include Rhopressa^® and Rocklatan^®, both aimed at reducing elevated intraocular pressure. Additionally, Aerie is expanding its portfolio with new candidates targeting other ophthalmic conditions.

Positive

• Aerie's market entry progress in Europe and Japan supports global expansion plans.
• The company highlights successful growth of its glaucoma franchise in the U.S.

Negative

• None.

DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie’s glaucoma franchise at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase. The slide presentation provides an update on Aerie’s franchise growth in the United States, as well as progress toward market entry in Europe and Japan.

The slide presentation from today’s event is available now and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for the treatment of dry eye disease, wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005089/en/

Ami Bavishi 908-947-3949; abavishi@aeriepharma.com

Source: Aerie Pharmaceuticals, Inc.

FAQ

What updates did Aerie Pharmaceuticals provide about its glaucoma franchise?

Aerie Pharmaceuticals showcased its growth in the U.S. and progress towards entering Europe and Japan.

What products does Aerie Pharmaceuticals offer for glaucoma treatment?

Aerie offers Rhopressa^® and Rocklatan^® for the treatment of open-angle glaucoma.

When was Rhopressa^® launched?

Rhopressa^® was launched in the U.S. in April 2018.

What is the purpose of the Ophthalmology Innovation Summit?

The summit focuses on innovations in ophthalmology, including advancements in glaucoma treatments.